Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
Solid-phase extraction technology can be used in a variety of research and discovery applications.
Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas.
Evotec reports that it is the first pharmaceutical contract research organization in Europe to offer these services. Its Hamburg site will house this Agilent technology including multiple RapidFire systems and 6460 Triple Quadrupole instrumentation.
“Evotec is the ideal partner for Agilent Technologies as we expand this industry-leading platform into the European contract research market,” says Gustavo Salem, Agilent vp and GM, biological systems division. “Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard mass spectrometry platforms.”
Agilent obtained the RapidFire system when it acquired Biocius Life Sciences last March. The screening technology provides results 10 to 100 times faster than traditional methods, according to Agilent.